These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

426 related items for PubMed ID: 23597716

  • 1. Have changing pneumococcal vaccination programmes impacted disease in Ontario?
    Lim GH, Wormsbecker AE, McGeer A, Pillai DR, Gubbay JB, Rudnick W, Low DE, Green K, Crowcroft NS, Deeks SL.
    Vaccine; 2013 May 31; 31(24):2680-5. PubMed ID: 23597716
    [Abstract] [Full Text] [Related]

  • 2. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007-2017.
    Wijayasri S, Hillier K, Lim GH, Harris TM, Wilson SE, Deeks SL.
    PLoS One; 2019 May 31; 14(12):e0226353. PubMed ID: 31834926
    [Abstract] [Full Text] [Related]

  • 3. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011.
    Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, Devlin R, Downey J, Katz K, Kitai I, Krajden S, Ostrowska K, Richardson D, Richardson S, Sarabia A, Silverman M, Simor AE, Tyrrell G, McGeer A, Toronto Invasive Bacterial Diseases Network.
    Vaccine; 2013 Dec 02; 31(49):5863-71. PubMed ID: 24099873
    [Abstract] [Full Text] [Related]

  • 4. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 5. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S, Menzies R, Chiu C, Toms C, Blyth CC, Krause V, McIntyre P.
    Clin Infect Dis; 2017 Jan 15; 64(2):175-183. PubMed ID: 27986682
    [Abstract] [Full Text] [Related]

  • 6. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T.
    Clin Microbiol Infect; 2013 Oct 15; 19 Suppl 1():1-9. PubMed ID: 24083785
    [Abstract] [Full Text] [Related]

  • 7. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M, Christopoulou D, Schmitt HJ.
    BMC Infect Dis; 2015 Oct 14; 15():419. PubMed ID: 26468008
    [Abstract] [Full Text] [Related]

  • 8. Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.
    Wagenvoort GH, Sanders EA, Vlaminckx BJ, de Melker HE, van der Ende A, Knol MJ.
    Euro Surveill; 2017 Mar 09; 22(10):. PubMed ID: 28300529
    [Abstract] [Full Text] [Related]

  • 9. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R, Bliss SJ, Larzelere-Hinton F, Eagle KJ, McGinty DJ, Parkinson AJ, Santosham M, Craig MJ, O'Brien KL.
    Clin Infect Dis; 2008 Aug 15; 47(4):476-84. PubMed ID: 18627249
    [Abstract] [Full Text] [Related]

  • 10. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D, Microbiologists of Epibac, ORP Networks.
    Vaccine; 2015 Jan 03; 33(2):359-66. PubMed ID: 25448105
    [Abstract] [Full Text] [Related]

  • 11. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E.
    Lancet Infect Dis; 2015 May 03; 15(5):535-43. PubMed ID: 25801458
    [Abstract] [Full Text] [Related]

  • 12. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E, Albert MJ.
    Vaccine; 2012 Dec 31; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [Abstract] [Full Text] [Related]

  • 13. Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012.
    Aguiar SI, Brito MJ, Horacio AN, Lopes JP, Ramirez M, Melo-Cristino J, Portuguese Group for the Study of Streptococcal Infections, Portuguese Study Group of Invasive Pneumococcal Disease of the Paediatric Infectious Disease Society.
    Euro Surveill; 2014 Mar 27; 19(12):20750. PubMed ID: 24698140
    [Abstract] [Full Text] [Related]

  • 14. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
    Link-Gelles R, Taylor T, Moore MR, Active Bacterial Core Surveillance Team.
    Vaccine; 2013 May 24; 31(22):2572-7. PubMed ID: 23583813
    [Abstract] [Full Text] [Related]

  • 15. Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.
    Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.
    Pediatr Infect Dis J; 2013 Jun 24; 32(6):604-9. PubMed ID: 23348816
    [Abstract] [Full Text] [Related]

  • 16. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P, Lefebvre B, Deceuninck G, Longtin J.
    Vaccine; 2018 Jan 08; 36(3):421-426. PubMed ID: 29224962
    [Abstract] [Full Text] [Related]

  • 17. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R.
    Pediatr Infect Dis J; 2009 Apr 08; 28(4):277-82. PubMed ID: 19258924
    [Abstract] [Full Text] [Related]

  • 18. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2010 Dec 10; 59(RR-11):1-18. PubMed ID: 21150868
    [Abstract] [Full Text] [Related]

  • 19. Serotypes and clones causing invasive pneumococcal disease before the use of new conjugate vaccines in Catalonia, Spain.
    Muñoz-Almagro C, Ciruela P, Esteva C, Marco F, Navarro M, Bartolome R, Sauca G, Gallés C, Morta M, Ballester F, Raga X, Selva L, Catalan study group of invasive pneumococcal disease.
    J Infect; 2011 Aug 10; 63(2):151-62. PubMed ID: 21679725
    [Abstract] [Full Text] [Related]

  • 20. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.
    Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG, Toronto Bacterial Diseases Network, Canadian Public Health Laboratory Network.
    Can J Microbiol; 2013 Dec 10; 59(12):778-88. PubMed ID: 24313450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.